Is STTK or MAZE more profitable?

Maze Therapeutics' return on equity of -36.62% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -60.73% -55.75% Maze Therapeutics N/A -36.62% -31.78%

Is DMRA or STTK more profitable?

Shattuck Labs' return on equity of -60.73% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62% Shattuck Labs N/A -60.73% -55.75%

Which has stronger earnings and valuation, AVLN or STTK?

Avalyn Pharma has higher earnings, but lower revenue than Shattuck Labs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalyn Pharma N/A N/A N/A N/A N/A Shattuck Labs $1M 413.31 -$48.81M -$0.63 N/A

Is AVLN or STTK more profitable?

Avalyn Pharma's return on equity of 0.00% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Avalyn Pharma N/A N/A N/A Shattuck Labs N/A -60.73% -55.75%

Shattuck Labs (STTK) Competitors

$5.39 +0.15 (+2.86%)

Closing price 04:00 PM Eastern

Extended Trading

$5.28 -0.11 (-1.95%)

As of 06:16 PM Eastern

Compare

STTK vs. MAZE, MRVI, PAHC, DMRA, and AVLN

Should you buy Shattuck Labs stock or one of its competitors? MarketBeat compares Shattuck Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Shattuck Labs include Maze Therapeutics (MAZE), Maravai LifeSciences (MRVI), Phibro Animal Health (PAHC), Damora Therapeutics, Inc. Common Stock (DMRA), and Avalyn Pharma (AVLN). These companies are all part of the "pharmaceutical products" industry.

How does Shattuck Labs compare to Maze Therapeutics?

Shattuck Labs (NASDAQ:STTK) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Shattuck Labs currently has a consensus target price of $11.00, indicating a potential upside of 104.08%. Maze Therapeutics has a consensus target price of $66.00, indicating a potential upside of 149.91%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Maze Therapeutics is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

58.7% of Shattuck Labs shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Shattuck Labs has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.27, meaning that its stock price is 127% more volatile than the broader market.

In the previous week, Maze Therapeutics had 2 more articles in the media than Shattuck Labs. MarketBeat recorded 2 mentions for Maze Therapeutics and 0 mentions for Shattuck Labs. Maze Therapeutics' average media sentiment score of 1.67 beat Shattuck Labs' score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Shattuck Labs	Neutral
Maze Therapeutics	Very Positive

Maze Therapeutics' return on equity of -36.62% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Maze Therapeutics	N/A	-36.62%	-31.78%

Shattuck Labs has higher earnings, but lower revenue than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	413.31	-$48.81M	-$0.63	N/A
Maze Therapeutics	$20M	73.08	-$131.12M	-$2.53	N/A

Summary

Maze Therapeutics beats Shattuck Labs on 9 of the 16 factors compared between the two stocks.

How does Shattuck Labs compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

Shattuck Labs has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
Shattuck Labs	N/A	-60.73%	-55.75%

Maravai LifeSciences has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 8.8% of Shattuck Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Maravai LifeSciences presently has a consensus target price of $5.50, indicating a potential upside of 2.42%. Shattuck Labs has a consensus target price of $11.00, indicating a potential upside of 104.08%. Given Shattuck Labs' stronger consensus rating and higher possible upside, analysts plainly believe Shattuck Labs is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Shattuck Labs has lower revenue, but higher earnings than Maravai LifeSciences. Shattuck Labs is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	7.46	-$130.77M	-$0.71	N/A
Shattuck Labs	$1M	413.31	-$48.81M	-$0.63	N/A

In the previous week, Maravai LifeSciences had 1 more articles in the media than Shattuck Labs. MarketBeat recorded 1 mentions for Maravai LifeSciences and 0 mentions for Shattuck Labs. Maravai LifeSciences' average media sentiment score of 1.34 beat Shattuck Labs' score of 0.00 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Overall Sentiment
Maravai LifeSciences	Positive
Shattuck Labs	Neutral

Summary

Shattuck Labs beats Maravai LifeSciences on 10 of the 16 factors compared between the two stocks.

How does Shattuck Labs compare to Phibro Animal Health?

Phibro Animal Health (NASDAQ:PAHC) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by company insiders. Comparatively, 8.8% of Shattuck Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Phibro Animal Health had 3 more articles in the media than Shattuck Labs. MarketBeat recorded 3 mentions for Phibro Animal Health and 0 mentions for Shattuck Labs. Phibro Animal Health's average media sentiment score of 0.31 beat Shattuck Labs' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Overall Sentiment
Phibro Animal Health	Neutral
Shattuck Labs	Neutral

Phibro Animal Health has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

Phibro Animal Health currently has a consensus price target of $42.50, indicating a potential upside of 39.21%. Shattuck Labs has a consensus price target of $11.00, indicating a potential upside of 104.08%. Given Shattuck Labs' stronger consensus rating and higher possible upside, analysts plainly believe Shattuck Labs is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Phibro Animal Health has a net margin of 6.35% compared to Shattuck Labs' net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.35%	37.14%	8.57%
Shattuck Labs	N/A	-60.73%	-55.75%

Phibro Animal Health has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.30B	0.96	$48.26M	$2.33	13.10
Shattuck Labs	$1M	413.31	-$48.81M	-$0.63	N/A

Summary

Phibro Animal Health beats Shattuck Labs on 11 of the 16 factors compared between the two stocks.

How does Shattuck Labs compare to Damora Therapeutics, Inc. Common Stock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

Shattuck Labs' return on equity of -60.73% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
Shattuck Labs	N/A	-60.73%	-55.75%

Shattuck Labs has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Shattuck Labs is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A
Shattuck Labs	$1M	413.31	-$48.81M	-$0.63	N/A

Damora Therapeutics, Inc. Common Stock has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

Damora Therapeutics, Inc. Common Stock presently has a consensus target price of $42.43, indicating a potential upside of 84.95%. Shattuck Labs has a consensus target price of $11.00, indicating a potential upside of 104.08%. Given Shattuck Labs' higher possible upside, analysts clearly believe Shattuck Labs is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.00 equaled Shattuck Labs'average media sentiment score.

Company	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	Neutral
Shattuck Labs	Neutral

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by company insiders. Comparatively, 8.8% of Shattuck Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Shattuck Labs beats Damora Therapeutics, Inc. Common Stock on 9 of the 13 factors compared between the two stocks.

How does Shattuck Labs compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and Shattuck Labs (NASDAQ:STTK) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Avalyn Pharma's return on equity of 0.00% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Shattuck Labs	N/A	-60.73%	-55.75%

Avalyn Pharma has higher earnings, but lower revenue than Shattuck Labs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A
Shattuck Labs	$1M	413.31	-$48.81M	-$0.63	N/A

Avalyn Pharma currently has a consensus price target of $59.00, indicating a potential upside of 82.72%. Shattuck Labs has a consensus price target of $11.00, indicating a potential upside of 104.08%. Given Shattuck Labs' higher probable upside, analysts clearly believe Shattuck Labs is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

58.7% of Shattuck Labs shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Avalyn Pharma had 3 more articles in the media than Shattuck Labs. MarketBeat recorded 3 mentions for Avalyn Pharma and 0 mentions for Shattuck Labs. Avalyn Pharma's average media sentiment score of 0.00 equaled Shattuck Labs'average media sentiment score.

Company	Overall Sentiment
Avalyn Pharma	Neutral
Shattuck Labs	Neutral

Summary

Avalyn Pharma and Shattuck Labs tied by winning 5 of the 10 factors compared between the two stocks.

Get Shattuck Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STTK vs. The Competition

Export

Metric	Shattuck Labs	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$401.81M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-8.56	19.75	24.92	23.98
Price / Sales	413.31	331.30	528.51	109.04
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	4.15	8.29	10.79	6.50
Net Income	-$48.81M	$23.85M	$3.56B	$336.88M
7 Day Performance	24.48%	5.21%	1.67%	-0.22%
1 Month Performance	-11.64%	2.19%	0.43%	0.77%
1 Year Performance	433.66%	60.99%	32.84%	31.57%

Shattuck Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STTK Shattuck Labs	4.0402 of 5 stars	$5.39 +2.9%	$11.00 +104.1%	+447.6%	$401.81M	$1M	N/A	100	Gap Down
MAZE Maze Therapeutics	3.1638 of 5 stars	$23.86 -1.7%	$66.00 +176.6%	+128.7%	$1.32B	$167.50M	N/A	121	Positive News
MRVI Maravai LifeSciences	2.5174 of 5 stars	$5.01 +1.0%	$5.50 +9.8%	+154.9%	$1.29B	$185.74M	N/A	610	Positive News
PAHC Phibro Animal Health	4.8636 of 5 stars	$31.87 -1.3%	$38.80 +21.7%	+30.1%	$1.29B	$1.30B	13.68	2,475	Upcoming Earnings
DMRA Damora Therapeutics, Inc. Common Stock	2.0065 of 5 stars	$20.62 +2.7%	$42.43 +105.8%	+620.4%	$1.27B	N/A	N/A	40	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STTK) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Shattuck Labs (STTK) Competitors

STTK vs. MAZE, MRVI, PAHC, DMRA, and AVLN

How does Shattuck Labs compare to Maze Therapeutics?

Summary

How does Shattuck Labs compare to Maravai LifeSciences?

Summary

How does Shattuck Labs compare to Phibro Animal Health?

Summary

How does Shattuck Labs compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Shattuck Labs compare to Avalyn Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK vs. The Competition

Shattuck Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Shattuck Labs (STTK) Competitors

STTK vs. MAZE, MRVI, PAHC, DMRA, and AVLN

How does Shattuck Labs compare to Maze Therapeutics?

Do analysts recommend STTK or MAZE?

Do insiders and institutionals believe in STTK or MAZE?

Which has more volatility & risk, STTK or MAZE?

Does the media refer more to STTK or MAZE?

Is STTK or MAZE more profitable?

Which has higher earnings and valuation, STTK or MAZE?

Summary

How does Shattuck Labs compare to Maravai LifeSciences?

Is MRVI or STTK more profitable?

Which has more volatility and risk, MRVI or STTK?

Do institutionals & insiders believe in MRVI or STTK?

Do analysts prefer MRVI or STTK?

Which has preferable valuation and earnings, MRVI or STTK?

Does the media prefer MRVI or STTK?

Summary

How does Shattuck Labs compare to Phibro Animal Health?

Do insiders & institutionals believe in PAHC or STTK?

Does the media prefer PAHC or STTK?

Which has more volatility and risk, PAHC or STTK?

Do analysts prefer PAHC or STTK?

Is PAHC or STTK more profitable?

Which has higher earnings and valuation, PAHC or STTK?

Summary

How does Shattuck Labs compare to Damora Therapeutics, Inc. Common Stock?

Is DMRA or STTK more profitable?

Which has preferable valuation and earnings, DMRA or STTK?

Which has more risk & volatility, DMRA or STTK?

Do analysts prefer DMRA or STTK?

Does the media prefer DMRA or STTK?

Do insiders and institutionals believe in DMRA or STTK?

Summary

How does Shattuck Labs compare to Avalyn Pharma?

Is AVLN or STTK more profitable?

Which has stronger earnings and valuation, AVLN or STTK?

Do analysts recommend AVLN or STTK?

Do institutionals & insiders believe in AVLN or STTK?

Does the media prefer AVLN or STTK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK vs. The Competition

Shattuck Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools